These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2390771)

  • 1. Media- and method-dependent variation in MIC values of ceftizoxime for clinical isolates of the Bacteroides fragilis group.
    Wexler HM; Finegold SM
    Clin Ther; 1990; 12 Suppl C():13-24. PubMed ID: 2390771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Media- and method-dependent variation in MIC values of ceftizoxime for clinical isolates of the Bacteroides fragilis group.
    Wexler HM; Finegold SM
    J Chemother; 1991 Feb; 3 Suppl 2():12-9. PubMed ID: 2040893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of in vivo and in vitro efficacy of ceftizoxime.
    Delaney ML; Cisneros RL; Onderdonk AB
    Clin Ther; 1990; 12 Suppl C():25-30. PubMed ID: 2390772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the in vitro activity of ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against clinically significant anaerobic bacteria.
    Aldridge KE
    Clin Ther; 1990; 12 Suppl C():3-12. PubMed ID: 2202509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the E-test for susceptibility testing of the Bacteroides fragilis group. Danish study group.
    Bremmelgaard A; Jansen JE; Justesen T; Gottschau A
    APMIS; 1994 Jun; 102(6):446-50. PubMed ID: 8068304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of sulfamethoxazole trimethoprim against Bacteroides fragilis.
    Nadaud M
    Zentralbl Bakteriol Orig A; 1978 Nov; 242(1):79-84. PubMed ID: 735555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of EUCAST disk diffusion method for susceptibility testing of the Bacteroides fragilis group isolates.
    Nagy E; Justesen US; Eitel Z; Urbán E;
    Anaerobe; 2015 Feb; 31():65-71. PubMed ID: 25464140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducible metronidazole resistance in nim-positive and nim-negative bacteroides fragilis group strains after several passages metronidazole containing columbia agar plates.
    Schaumann R; Petzold S; Fille M; Rodloff AC
    Infection; 2005 Oct; 33(5-6):368-72. PubMed ID: 16258869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of the oxa-beta-lactam LY 127935 against Bacteroides fragilis and other anaerobic gram-negative rods (author's transl)].
    Werner H; Krasemann C
    Infection; 1980; 8 Suppl 3():S 342-6. PubMed ID: 6447673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
    Goldstein EJ; Citron DM
    J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of inoculum size and medium on activity of seven antimicrobial agents against Bacteroides fragilis strains.
    Wexler HM; Reeves D; Finegold SM
    Clin Ther; 1989; 11(6):828-33. PubMed ID: 2611824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
    Stearne LE; Goessens WH; Mouton JW; Gyssens IC
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3605-11. PubMed ID: 17646416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
    Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
    Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of in vitro antibiograms of Bacteroides fragilis group isolates: differences in resistance rates in two institutions because of differences in susceptibility testing methodology.
    Aldridge KE; Wexler HM; Sanders CV; Finegold SM
    Antimicrob Agents Chemother; 1990 Jan; 34(1):179-81. PubMed ID: 2327757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of tigecycline against Bacteroides species.
    Betriu C; Culebras E; Gómez M; Rodríguez-Avial I; Picazo JJ
    J Antimicrob Chemother; 2005 Aug; 56(2):349-52. PubMed ID: 15951353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major methodology-dependent discordant susceptibility results for Bacteroides fragilis group isolates but not other anaerobes.
    Aldridge KE; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):135-42. PubMed ID: 7874880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
    Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez H
    Antimicrob Agents Chemother; 2006 Jan; 50(1):148-55. PubMed ID: 16377680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sensitivity of anaerobes to 8 antibiotics].
    Sedallian A
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):645-7. PubMed ID: 3534760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group.
    Snydman DR; Jacobus NV; McDermott LA
    J Antimicrob Chemother; 2005 Jun; 55(6):1024-8. PubMed ID: 15824092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the in vitro inhibitory and bactericidal activity of ceftizoxime, cefoxitin, cefotetan, and penicillin G against Bacteroides fragilis group isolates. Comparison of time-kill kinetic studies with MIC values.
    Aldridge KE; Weeks LS; Stratton CW; Sanders CV
    Diagn Microbiol Infect Dis; 1990; 13(4):311-6. PubMed ID: 2076592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.